Effect of antiplatelet pretreatment on safety and efficacy outcomes in acute ischemic stroke patients after intravenous thrombolysis: a systematic review and meta-analysis

References

• Wardlaw JM, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet. 2012;379(9834):2364–2372.
   Google Scholar
• Qureshi AI, Kirmani JF, Safdar A, et al. High prevalence of previous antiplatelet drug use in patients with new or recurrent ischemic stroke: buffalo metropolitan area and Erie County stroke study. Pharmacotherapy. 2006;26(4):493–498.
   PubMed Web of Science ®Google Scholar
• Anderson CS, Robinson T, Lindley RI, et al. Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke. N Engl J Med. 2016;374(24):2313–2323.
   PubMed Web of Science ®Google Scholar
• Xian Y, Federspiel JJ, Grau-Sepulveda M, et al. Risks and benefits associated with prestroke antiplatelet therapy among patients with acute ischemic stroke treated with intravenous tissue plasminogen activator. JAMA Neurol. 2016;73(1):50–59.
   PubMed Web of Science ®Google Scholar
• Sanak D, Kuliha M, Herzig R, et al. Prior use of antiplatelet therapy can be associated with a higher chance for early recanalization of the occluded middle cerebral artery in acute stroke patients treated with intravenous thrombolysis. Eur Neurol. 2012;67(1):52–56.
   PubMed Web of Science ®Google Scholar
• Pan X, Zhu Y, Zheng D, et al. Prior antiplatelet agent use and outcomes after intravenous thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke: a meta-analysis of cohort studies and randomized controlled trials. Int J Stroke. 2015;10(3):317–323.
   PubMed Web of Science ®Google Scholar
• Luo S, Zhuang M, Zeng W, et al. Intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy: a systematic review and meta-analysis of 19 studies. J Am Heart Assoc. 2016;5(5):pii:e003242.
   Web of Science ®Google Scholar
• Tsivgoulis G, Katsanos AH, Zand R, et al. Antiplatelet pretreatment and outcomes in intravenous thrombolysis for stroke: a systematic review and meta-analysis. J Neurol. 2017;264(6):1227–1235.
   PubMed Web of Science ®Google Scholar
• Bembenek JP, Niewada M, Karlinski M, et al. Effect of prestroke antiplatelets use on first-ever ischaemic stroke severity and early outcome. Int J Clin Pract. 2016;70(6):477–481.
   PubMed Web of Science ®Google Scholar
• Chen S, Lu X, Zhang W, et al. Does prior antiplatelet treatment increase the risk of hemorrhagic transformation and unfavorable outcome on day 90 after intravenous thrombolysis in acute ischemic stroke patients? J Stroke Cerebrovasc Dis. 2016;25(6):1366–1370.
   PubMed Web of Science ®Google Scholar
• Choi JC, Lee JS, Park TH, et al. Prestroke antiplatelet effect on symptomatic intracranial hemorrhage and functional outcome in intravenous thrombolysis. J Stroke. 2016;18(3):344–351.
   PubMed Web of Science ®Google Scholar
• Tsivgoulis G, Katsanos AH, Mavridis D, et al. Intravenous thrombolysis for ischemic stroke patients on dual antiplatelets. Ann Neurol. 2018;84(1):89–97.
   PubMed Web of Science ®Google Scholar
• Tsivgoulis G, Goyal N, Kerro A, et al. Dual antiplatelet therapy pretreatment in IV thrombolysis for acute ischemic stroke. Neurology. 2018;91(11):e1067–e1076.
   PubMed Web of Science ®Google Scholar
• Robinson TG, Wang X, Arima H, et al. ENCHANTED investigators. low-versus standard-dose alteplase in patients on prior antiplatelet therapy: the ENCHANTED trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study). Stroke. 2017;48(7):1877–1883.
   PubMed Web of Science ®Google Scholar
• Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [cited 2018]. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
   Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558.
   PubMed Web of Science ®Google Scholar
• Cucchiara B, Kasner SE, Tanne D, et al. SAINT Investigators. Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke: pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II trials. Stroke. 2009;40(9):3067–3072.
   PubMed Web of Science ®Google Scholar
• Kicinski M, Springate DA, Kontopantelis E. Publication bias in meta-analyses from the cochrane database of systematic reviews. Stat Med. 2015;34(20):2781–2793.
   PubMed Web of Science ®Google Scholar
• Bravo Y, Marti-Fabregas J, Cocho D, et al. Influence of antiplatelet pre-treatment on the risk of symptomatic intracranial haemorrhage after intravenous thrombolysis. Cerebrovasc Dis. 2008;26(2):126–133.
   PubMed Web of Science ®Google Scholar
• Dharmasaroja PA, Dharmasaroja P, Muengtaweepongsa S. Outcomes of Thai patients with acute ischemic stroke after intravenous thrombolysis. J Neurol Sci. 2011;300(1–2):74–77.
   PubMed Web of Science ®Google Scholar
• Diedler J, Ahmed N, Sykora M, et al. Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. Stroke. 2010;41(2):288–294.
   PubMed Web of Science ®Google Scholar
• Dorado L, Millan M, de la Ossa NP, et al. Influence of antiplatelet pre-treatment on the risk of intracranial haemorrhage in acute ischaemic stroke after intravenous thrombolysis. Eur J Neurol. 2010;17(2):301–306.
   PubMed Web of Science ®Google Scholar
• Frank B, Grotta JC, Alexandrov AV, et al. VISTA collaborators. Thrombolysis in stroke despite contraindications or warnings. Stroke. 2013;44(3):727–733.
   PubMed Web of Science ®Google Scholar
• Hacke W, Kaste M, Bluhmki E, et al. ECASS investigators. thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317–1329.
   PubMed Web of Science ®Google Scholar
• Hermann A, Dzialowski I, Koch R, et al. Combined anti-platelet therapy with aspirin and clopidogrel: risk factor for thrombolysis-related intracerebral hemorrhage in acute ischemic stroke? J Neurol Sci. 2009;284(1–2):155–157.
   PubMed Web of Science ®Google Scholar
• Ibrahim MM, Sebastian J, Hussain M, et al. CLOTBUST Investigators. Does current oral antiplatelet agent or subtherapeutic anticoagulation use have an effect on tissue-plasminogen-activator-mediated recanalization rate in patients with acute ischemic stroke? Cerebrovasc Dis. 2010;30(5):508–513.
   PubMed Web of Science ®Google Scholar
• Lindley RI, Wardlaw JM, Whiteley WN, et al. IST-3 collaborative group. Alteplase for acute ischemic stroke: outcomes by clinically important subgroups in the third international stroke trial. Stroke. 2015;46(3):746–756.
   PubMed Web of Science ®Google Scholar
• Meseguer E, Labreuche J, Guidoux C, et al. Outcomes after stroke thrombolysis according to prior antiplatelet use. Int J Stroke. 2015;10(2):163–169.
   PubMed Web of Science ®Google Scholar
• Pan Y, Chen Q, Liao X, et al. TIMS-China Investigators. Preexisting dual antiplatelet treatment increases the risk of post-thrombolysis intracranial hemorrhage in Chinese stroke patients. Neurol Res. 2015;37(1):64–68.
   PubMed Web of Science ®Google Scholar
• Strbian D, Engelter S, Michel P, et al. Symptomatic intracranial hemorrhage after stroke thrombolysis: the SEDAN score. Ann Neurol. 2012;71(5):634–641.
   PubMed Web of Science ®Google Scholar
• Tanne D, Kasner SE, Demchuk AM, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation. 2002;105(14):1679–1685.
   PubMed Web of Science ®Google Scholar
• Uyttenboogaart M, Koch MW, Koopman K, et al. Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke. Arch Neurol. 2008;65(5):607–611.
   PubMedGoogle Scholar
• National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581–1587.
   PubMed Web of Science ®Google Scholar
• Dachs RJ, Burton JH, Joslin J. A user’s guide to the NINDS rt-PA stroke trial database. PLoS Med. 2008;5(5):e113.
   PubMed Web of Science ®Google Scholar
• Larrue V, von Kummer RR, Müller A, et al. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke. 2001;32(2):438–441.
   PubMed Web of Science ®Google Scholar
• Wahlgren N, Ahmed N, Eriksson N, et al. Safe implementation of thrombolysis in stroke-monitoring study investigators. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST). Stroke. 2008;39(12):3316–3322.
   PubMed Web of Science ®Google Scholar
• Kernan WN, Ovbiagele B, Black HR, et al. American heart association stroke council, council on cardiovascular and stroke nursing, council on clinical cardiology, and council on peripheral vascular disease. guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke. 2014;45(7):2160–2236.
   PubMed Web of Science ®Google Scholar
• Estol CJ, Bath PM, Gorelick PB, et al. PRoFESS publications committee and PRoFESS investigators. Differences in ischemic and hemorrhagic recurrence rates among race-ethnic groups in the PRoFESS secondary stroke prevention trial. Int J Stroke. 2014;9(Suppl A100):43–47.
   PubMedGoogle Scholar
• Ge F, Lin H, Liu Y, et al. Dual antiplatelet therapy after stroke or transient ischaemic attack - how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis. Eur J Neurol. 2016;23(6):1051–1057.
   PubMed Web of Science ®Google Scholar
• Hong KS, Lee SH, Kim EG, et al. COMPRESS investigators. recurrent ischemic lesions after acute atherothrombotic stroke: clopidogrel plus aspirin versus aspirin alone. Stroke. 2016;47(9):2323–2330.
   PubMed Web of Science ®Google Scholar
• Benavente OR, Hart RG, McClure LA, et al. SPS3 Investigators. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012;367(9):817–825.
   PubMed Web of Science ®Google Scholar